Stock XTLB XTL BIOPHARMACEUTICALS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News XTL Biopharmaceuticals Ltd.

Equities

XTLB

IL0010854979

Market Closed - TEL AVIV STOCK EXCHANGE
Other stock markets
 10:24:25 2024-06-06 am EDT 		5-day change 1st Jan Change
8.9 ILa -3.26% Intraday chart for XTL Biopharmaceuticals Ltd. -4.30% +154.29%
Jun. 05 XTL Biopharmaceuticals Signs Deal to Acquire The Social Proxy MT
May. 13 XTL Biopharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
XTL Biopharmaceuticals Signs Deal to Acquire The Social Proxy
MT
XTL Biopharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Top Premarket Gainers
MT
XTL Biopharmaceuticals : Report Of Foreign Private Issuer - Form 6-K
PU
XTL Biopharmaceuticals : Immediate Report of Meeting
PU
XTL Biopharmaceuticals : NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 30, 2024 - Form 6-K
PU
Top Midday Gainers
MT
XTL Biopharmaceuticals to Acquire The Social Proxy; Shares Soar
MT
XTL To Aquire The Social Proxy
AQ
XTL Biopharmaceuticals Ltd. announced that it expects to receive $1.5 million in funding
CI
XTL Biopharmaceuticals Ltd. entered into a binding term sheet to acquire THE SOCIAL PROXY Ltd.
CI
XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
XTL Biopharmaceuticals : Report Of Foreign Private Issuer - Form 6-K
PU
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
AQ
XTL Biopharmaceuticals : OPERATING AND FINANCIAL REVIEW AND PROSPECTS (Form 6-K)
PU
XTL Biopharmaceuticals Ltd. Elects Alexander Rabinovitch as Directors
CI
XTL Biopharmaceuticals Appoints Alex Rabinovich to its Board of Directors
CI
XTL Biopharmaceuticals Ltd. Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s Syndrome
CI
XTL Biopharmaceuticals Ltd. Announces Resignation David Kestenbaum as Chief Financial Officer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XTLB Stock
  4. News XTL Biopharmaceuticals Ltd.